Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Tema Etfs LLC

Tema Etfs LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.4% in the second quarter, HoldingsChannel reports. The firm owned 5,307 shares of the biopharmaceutical company’s stock after acquiring an additional 1,007 shares during the period. Tema Etfs LLC’s holdings in Regeneron Pharmaceuticals were worth $2,786,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of REGN. Marshall Wace LLP increased its stake in Regeneron Pharmaceuticals by 533.0% during the 2nd quarter. Marshall Wace LLP now owns 239,909 shares of the biopharmaceutical company’s stock valued at $125,952,000 after buying an additional 202,009 shares during the period. Dodge & Cox lifted its stake in Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares during the last quarter. Veltria Advisors Corp. boosted its holdings in Regeneron Pharmaceuticals by 30.1% during the second quarter. Veltria Advisors Corp. now owns 462 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 107 shares in the last quarter. Great Diamond Partners LLC boosted its holdings in Regeneron Pharmaceuticals by 25.3% during the second quarter. Great Diamond Partners LLC now owns 535 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 108 shares in the last quarter. Finally, Baird Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 9.8% in the second quarter. Baird Financial Group Inc. now owns 48,979 shares of the biopharmaceutical company’s stock worth $25,714,000 after buying an additional 4,383 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 7.02% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. HSBC began coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 price objective for the company. Truist Financial started coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $798.00 target price for the company. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday. Canaccord Genuity Group boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Scotiabank raised their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $777.36.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $722.80 on Friday. The firm has a 50 day simple moving average of $647.61 and a 200 day simple moving average of $587.69. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $800.99. The stock has a market cap of $75.97 billion, a P/E ratio of 17.31, a P/E/G ratio of 2.07 and a beta of 0.37. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $12.46 EPS. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.